Table 2.
Progression types and molecular subgroups according to The Cancer Genome Atlas analysis
| Placebo+ RT/TMZ | ||||||
|---|---|---|---|---|---|---|
| PN | N | Class | Mes | Unclass | Total | |
| Progression type | ||||||
| Classic T1 | 20 | 2 | 20 | 36 | 5 | 83 |
| cT1 relapse | 6 | 1 | 4 | 3 | 0 | 14 |
| T2 diffuse | 5 | 2 | 1 | 7 | 0 | 15 |
| T2 circumscribed | 0 | 0 | 1 | 1 | 1 | 3 |
| Primary nonresponder | 15 | 4 | 5 | 4 | 2 | 30 |
| 46 | 9 | 31 | 51 | 8 | 145 | |
| Chi-square = 27.6 degrees of freedom = 16 probability = 0.036 | ||||||
| Bevacizumab + RT/TMZ | ||||||
| PN | N | Class | Mes | Unclass | Total | |
| Progression type | ||||||
| Classic T1 | 11 | 1 | 8 | 8 | 0 | 28 |
| cT1 relapse | 12 | 1 | 13 | 17 | 4 | 47 |
| T2 diffuse | 9 | 1 | 5 | 3 | 3 | 21 |
| T2 circumscribed | 7 | 0 | 3 | 11 | 3 | 24 |
| Primary nonresponder | 1 | 0 | 2 | 1 | 0 | 4 |
| 40 | 3 | 31 | 40 | 10 | 124 | |
| Chi-square = 14.1 degrees of freedom = 16 probability = 0.589 | ||||||
Note: Molecular subtype classification according to Sandmann et al5 shows an association between primary nonresponders and the proneural subgroup but only in the placebo arm (15/30 proneural in the primary nonresponder PT . PN = proneural, N = neural, class = classical, mes = mesenchymal, unclass = not classified.